Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: jargonweary who wrote (975)	4/25/2025 10:05:39 AM
From: waitwatchwander	1 Recommendation Recommended By Fitzhughlaw Respond to of 1229

Without a big pharma partner the market for Anktiva is growing slower than the market expected. The initial expectation I remember was for $60M per quarter in sales. Working alone they have so far only garnered $7M and $16M todate. At this rate the $60M figure is still a few quarters down the road and that assumes the limited non responsive bladder cancer market doesn't get filled prior to this sales achievement. When one is extending duration of quality survival, the candle is burning at both ends.